Scarica l'app Stockscreener
164.91
2.43%
3.91
Dopo l'orario di chiusura:
160.46
-4.45
-2.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$161.00
Aprire:
$158.39
Volume 24 ore:
4.13M
Relative Volume:
1.36
Capitalizzazione di mercato:
$35.17B
Reddito:
$447.02M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-26.68
EPS:
-6.1812
Flusso di cassa netto:
$-906.14M
1 W Prestazione:
+10.86%
1M Prestazione:
+0.86%
6M Prestazione:
+27.39%
1 anno Prestazione:
+97.24%
Intervallo 1D:
$157.77
$167.37
Intervallo di 1 settimana:
$147.26
$167.37
Portata 52W:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
164.91 | 34.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Wells Fargo Lowers Price Target for Insmed (INSM) Amid Overweigh - GuruFocus
Breaking Down Insmed: 16 Analysts Share Their Views - Benzinga
Wall Street Analysts Think Insmed (INSM) Could Surge 33.6%: Read This Before Placing a Bet - Finviz
Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View - Bitget
Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says - marketscreener.com
Insmed May Top Revenue Target for Bronchiectasis Drug Brinsupri, Morgan Stanley Says - marketscreener.com
Insmed Incorporated (NASDAQ:INSM) Q4 2025 Earnings Call Transcript - Insider Monkey
Skandinaviska Enskilda Banken AB publ Grows Position in Insmed, Inc. $INSM - MarketBeat
Morgan Stanley Lifts Price Target on Insmed to $166 From $162, Keeps Equalweight Rating - marketscreener.com
Insmed, Inc. $INSM Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Insmed (INSM) Poised for 2026 Upside With Potential $1.3B Arikayce Sales Boost, Roth/MKM Initiates Buy - Finviz
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed jumps as new drug launch momentum drives bullish 2026 revenue outlook - Quiver Quantitative
Insmed Inc (INSM) Q4 2025 Earnings Call Highlights: Strong Brin Suri Launch and Promising 2026 ... By GuruFocus - Investing.com Canada
A Closer Look at Insmed's Options Market Dynamics - Benzinga
Insmed Inc (INSM) Q4 2025 Earnings Call Highlights: Strong Brin Suri Launch and Promising 2026 Revenue Outlook - GuruFocus
Insmed (INSM) Projects Significant Revenue Growth with BRINSUPRI's Success - GuruFocus
Insmed (NASDAQ:INSM) Issues Earnings Results - MarketBeat
Insmed Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance
Insmed (INSM) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Insmed Q4 2025 misses EPS, beats revenue By Investing.com - Investing.com UK
Insmed Q4 Earnings Call Highlights - Yahoo Finance
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Earnings call transcript: Insmed Q4 2025 misses EPS, beats revenue - Investing.com
Insmed Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Mcrae Capital Management Inc. Invests $3.92 Million in Insmed, Inc. $INSM - MarketBeat
Insmed (INSM) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Insmed: Q4 Earnings Snapshot - kens5.com
Insmed reports fourth-quarter and full-year 2025 financial results and provides business update - marketscreener.com
Insmed (INSM) Sets Ambitious Revenue Projections for 2026 - GuruFocus
Insmed Q4 Loss Widens, Revenue Rises - marketscreener.com
INSMED ($INSM) Releases Q4 2025 Earnings - Quiver Quantitative
INSMED Inc SEC 10-K Report - TradingView
Insmed Earnings Review: Q4 Summary - Benzinga
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update - PR Newswire
Vanguard Group Inc. Raises Holdings in Insmed, Inc. $INSM - MarketBeat
How Recent Analyst Shifts And Brinsupri Milestones Are Reframing The Insmed (INSM) Story - Yahoo Finance
Insmed: Fourth Quarter Financial Highlights - Bitget
Insmed earnings up next: Can Brinsupri sustain blockbuster start? By Investing.com - Investing.com Canada
Insmed earnings up next: Can Brinsupri sustain blockbuster start? - Investing.com Nigeria
Exploring Insmed's Earnings Expectations - Benzinga
Insmed, Inc. $INSM is Eagle Health Investments LP's 2nd Largest Position - MarketBeat
Bronchiectasis Clinical Trial Pipeline Expands as 15+ Pharma - openPR.com
Insmed, Inc. $INSM Shares Sold by Aberdeen Group plc - MarketBeat
What to Expect From These Drug/Biotech Players This Earnings Season? - TradingView
Tobam Takes Position in Insmed, Inc. $INSM - MarketBeat
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity? - Intellectia AI
Assessing Insmed (INSM) Valuation After Strong One Year Return And Recent Share Price Pullback - Yahoo Finance
TimesSquare Capital Management LLC Sells 448,406 Shares of Insmed, Inc. $INSM - MarketBeat
Does Insmed (INSM) Still Look Attractive After Recent Share Price Pullback? - Yahoo Finance
Insmed (INSM) expected to beat earnings estimates: Can the stock move higher? - MSN
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Feb 09 '26 |
Option Exercise |
24.94 |
10,699 |
266,840 |
314,581 |
| Lewis William | Chair and CEO |
Feb 09 '26 |
Sale |
147.79 |
13,396 |
1,979,764 |
301,185 |
2.16%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):